Drug Trial Radar · NCT07295873
Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Mar 15, 2026
Primary completion
May 29, 2026
Study completion May 29, 2026
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B. The commonly used chronic hepatitis B antiviral agents include Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF). This study aims to evaluate the drug-drug interaction (DDI) of Hydronidone Capsules 90 mg with Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF) respectively in healthy participants, to inform the preparation of post-marketing labeling and the development of concomitant dosing regimens in clinical practice.
Conditions
- Chronic Hepatitis B Liver Fibrosis
- DDI (Drug-Drug Interaction)
Interventions
EntecavirDrug
0.5 mg, taken orally on an empty stomach, once a day
Tenofovir Disoproxil Fumarate(TDF)Drug
300 mg, taken orally on an empty stomach, once a day
Tenofovir alafenamide(TAF)Drug
25 mg, single oral dose, under fasting conditions
Tenofovir Amibufenamide(TMF)Drug
25 mg, single oral dose, under fasting conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma hydronidone PK parameters of hydronidone capsules : steady-state peak concentration (Cmax,ss);Time frame: 23 days
- Plasma hydronidone PK parametersof hydronidone capsules : Area under the plasma concentration-time curve from time zero to 24 hours at steady state (AUC0-24h,ss)Time frame: 23 days
- Primary PK parameters of plasma of entecavir : AUC0-24h,ss.Time frame: 23 days
- Primary PK parameters of plasma of entecavir : Cmax,ss .Time frame: 23 days
- Primary PK parameters of plasma tenofovir alafenamide (TAF) : AUC0-24h,ss.Time frame: 23 days
- Primary PK parameters of plasma tenofovir alafenamide (TAF) : Cmax,ss .Time frame: 23 days
- Primary PK parameters of tenofovir disoproxil fumarate tablets (TDF): Cmax,ss .Time frame: 20 days
- Primary PK parameters of tenofovir disoproxil fumarate tablets (TDF): AUC0-24h,ss.Time frame: 20 days
- Primary PK parameters of plasma tenofovir amibufenamide (TMF) : Cmax,ss .Time frame: 23 days
- Primary PK parameters of plasma tenofovir amibufenamide (TMF) : AUC0-24h,ss.Time frame: 23 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Gaobo Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.